Multiple Myeloma Drugs Market 2025–2029: Tracking 6.3% CAGR Toward $29.44 Billion in Revenue

Uncover key drivers, emerging technologies, and competitive movements shaping the multiple myeloma drugs market from 2025–2034 with trusted insights from The Business Research Company

How Will The Multiple Myeloma Drugs Market Size Evolve Between Now And 2029?

The multiple myeloma drugs market size has experienced strong growth in recent years. It is anticipated to expand from $21.84 billion in 2024 to $23.03 billion in 2025, representing a compound annual growth rate (CAGR) of 5.4%. This growth observed in the past can be attributed to several factors including improved diagnosis, successful clinical trials, a greater understanding of disease biology, enhancements in healthcare infrastructure, increased patient advocacy, and heightened awareness.

The multiple myeloma drugs market size is anticipated to expand significantly in the upcoming years. It is forecast to achieve a valuation of $29.44 billion by 2029, exhibiting a compound annual growth rate (CAGR) of 6.3%. This projected growth throughout the forecast period stems from factors such as immunotherapy innovations, the expansion of targeted therapies, the application of liquid biopsy, the emergence of car-t cell therapy, and ongoing biomarker discovery. Notable trends anticipated during this period encompass a long-term survivorship focus, the exploration of epigenetic therapies, an expanded role for telemedicine, increased access to novel therapies, and a commitment to sustainability in myeloma care.

Access A Free Sample Of The Report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=11943&type=smp

Which Key Drivers Are Powering Growth In The Multiple Myeloma Drugs Market?

The increasing occurrence of hematological cancer is projected to propel the multiple myeloma drugs market forward. These cancers commence in blood-forming tissues, such as bone marrow, or immune system cells, including leukemia, lymphoma, multiple myeloma, and similar conditions. Multiple myeloma medications are commonly utilized to manage various myelomas by eliminating and restricting the proliferation of cancer cells, achieved by slowing down cell division through stimulating numerous enzymatic actions, while also helping bones maintain strength and alleviating pain in weakened skeletal areas. For example, in January 2023, the American Cancer Society (ACS), a US-based health organization dedicated to eradicating cancer, reported approximately 59,610 newly diagnosed cases of leukemia and about 20,380 cases of acute myeloid leukemia (AML). Additionally, the total number of fatalities attributed to leukemia reached 23,710. Thus, the rising prevalence of hematological cancer is driving the growth of the multiple myeloma drugs market.

How Is The Global Multiple Myeloma Drugs Market Structured By Key Segments?

The multiple myeloma drugs market covered in this report is segmented –

1) By Drug Type: Immunomodulatory Drugs, Proteasome Inhibitors, Histone Deacetylase Inhibitors, Monoclonal Antibody Drugs, Steroids, Other Drug Types

2) By Therapy: Targeted Therapy, Biologic Therapy, Chemotherapy, Other Therapies

3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Other Distribution Channels

4) By End-User: Men, Women

Subsegments:

1) By Immunomodulatory Drugs: Lenalidomide, Thalidomide, Pomalidomide

2) By Proteasome Inhibitors: Bortezomib, Carfilzomib, Ixazomib

3) By Histone Deacetylase Inhibitors: Panobinostat, Romidepsin

4) By Monoclonal Antibody Drugs: Daratumumab, Elotuzumab, Isatuximab

5) By Steroids: Dexamethasone, Prednisone

6) By Other Drug Types: Alkylating Agents, Antimetabolites, New Experimental Drugs

What Future-Focused Trends Are Anticipated In The Multiple Myeloma Drugs Market?

A prominent trend gaining traction in the multiple myeloma drugs market is product innovation. Leading companies operating within the multiple myeloma drugs market are concentrating on developing novel products to enhance their position and secure a competitive advantage. For example, in March 2022, Janssen Biotech Inc., a Japan-based biotechnology company, obtained United States Food and Drug Administration approval for Carvykti, a CAR T-Cell therapy (personalized immunotherapy) specifically for multiple myeloma. CARVYKTI (ciltacabtagene autoleucel) is a genetically modified autologous cell-based product where T cells are transduced ex vivo with a replication-incapable lentiviral vector. This vector encodes an anti-B cell maturation antigen (BCMA) chimeric antigen receptor (CAR) comprising two single domain antibodies linked to a 4-1BB costimulatory domain and a CD3-zeta signaling domain. Patients who have received four or more lines of therapy, including treatment with three critical kinds of multiple myeloma medications (an immunomodulating agent, a proteasome inhibitor, and an anti-CD38 monoclonal antibody), are eligible to receive this treatment for relapsed conditions.

Which Companies Hold A Competitive Edge In The Multiple Myeloma Drugs Market?

Major companies operating in the multiple myeloma drugs market include Pfizer Inc., Johnson & Johnson Pvt. Ltd, Merck & Co. Inc., AbbVie Inc., Bayer AG., Roche Holding AG, Novartis AG, Sanofi S.A., Bristol-Myers Squibb Company, GlaxoSmithKline Plc, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Kite Pharma Inc, Amgen Inc., AstraZeneca plc, Teva Pharmaceutical Industries Ltd., Regeneron Pharmaceuticals Inc., Daiichi Sankyo Company, Daiichi Sankyo Co. Ltd., Lonza Group AG, Cipla Ltd., ONO Pharmaceutical Co. Ltd., BieGene Ltd., Biotest AG, Onyx Pharmaceuticals Inc., PharmaMar SA, Karyopharm Therapeutics Inc., Poseida Therapeutics Inc., ImmunoGen Inc., Oncopetides AB

Download The Full Report Here:

https://www.thebusinessresearchcompany.com/report/multiple-myeloma-drugs-global-market-report

Which Region Is Expected To Lead The Multiple Myeloma Drugs Market In The Next Few Years?

North America was the largest region in the multiple myeloma drugs market in 2024. The regions covered in the multiple myeloma drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Get A Report Customized For You Here:

https://www.thebusinessresearchcompany.com/customise?id=11943&type=smp

Browse Through More Reports Similar to the Global Multiple Myeloma Drugs Market 2025, By The Business Research Company

Cardiovascular Drugs Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/cardiovascular-drugs-global-market-report

Dermatology Drugs Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/dermatology-drugs-global-market-report

Gastrointestinal Drug Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/gastrointestinal-drug-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795